Mi Meng

Sitravatinib combined with osimertinib overcomes acquired osimertinib resistance in NSCLC by targeting AXL and the PI3K/AKT/GSK3β signaling pathway

The emergence of acquired resistance to osimertinib has emerged as a severe plight in the clinical management of patients with advanced harboring epidermal growth factor receptor mutations non-small cell lung (NSCLC). We comprehensively evaluated sitravatinib, an emerging multita...